drugset / Trial / NCT02473510

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season

NCT02473510

Phase 4 Completed 301 enrolled MedImmune LLC AstraZeneca · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This prospective annual release study is designed to evaluate the safety of 3 new influenza virus vaccine strains to be included in FluMist Quadrivalent for the 2015-2016 influenza season

Timeline

Start
2015-06
Primary completion
2016-01
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Influenza Virus Vaccine Vaccine 1e+07 unknown Intranasal

Indications